Sylvain THIERRY has over 20 years of experience, including 11 years in the development of innovative therapies in the field of infectious diseases and cancers, in close cooperation with academics, clinicians and pharmaceutical industries. With a PhD in immuno-virology and a degree in Immunotherapies, Sylvain THIERRY is a Senior scientist with a peer review of 22 scientific publications and 2 patents.
Expert in immunogenicity, DAMPs, PAMPs, DNA repair and oligonucleotide-based therapeutics, he also has strong group leadership in the domain of translational research, from the discovery to the early-clinical development.
Sylvain THIERRY began his career in discovering the immunogenic properties of HMGB1 in infectious diseases. First in AIDS during his thesis at the “Cordeliers Research Center” and then in Malaria, during two years as Associate-Professor at the “Pierre & Marie Curie University”. Then, he joined the “ENS-Paris-Saclay” as Junior Principal Investigator in applied pharmacology for 5 years – by obtaining grants from the ANRS and Sidaction – where he developed clinical diagnostics and innovative therapies in AIDS and Cancer (WO2013186718). In 2014, he joined the “Curie Institute” for 4 years as Scientific Coordinator of an INCa-TRANSLA preclinical project for innovative therapies, that leads to a successful Phase-I clinical-trial using a systemic administration of oligonucleotides in solid cancers.
Sylvain THIERRY joined Tollys in 2018, where he contributed to the creation of a new family of dsRNAs oligonucleotides, as innovative therapy in solid cancers (WO2019211492 Bonnin M and Thierry S). He is now leading the translational research group using these drug candidates in the perspective of clinical-trials.
Cutting-Edge Cancer Immunotherapy
60F avenue Rockefeller
69008 Lyon, FRANCE